Historically slow to adapt, the pharma industry acted fast when the pandemic hit. Vaccines were developed in an unprecedented amount of time and robust supply chains quickly distributed the new drugs around the world showing the possibility that pandemic-forced innovation holds. While no small feat, pharma companies achieved the unthinkable all the while managing the workforce safely and navigating government restrictions. 

Now it’s time to look at what’s next and brace for unavoidable market transformations. While individual companies will drive many of these changes, some will be driven by industry-wide and external factors, including government involvement. 

In this session, ISG’s Jenn Stein and Bayer’s Melissa Saw analyze the changes that have occurred over the past 15 months and lay down predictions of what’s to come. 
 

Key Takeaways include:

• What changes in the general healthcare sector have occurred as a result of the pandemic?
• What challenges do pharma companies need to overcome in order to advance post-pandemic? 
• What implications does this have on patient and consumer groups and healthcare professionals? 
• How are patient and consumer expectations shifting, and what are pharma companies doing to address them?
• What are pharma companies doing to reinvent their relevance? 
• What opportunities can be learned from consumer marketplaces and tech giants like Amazon that are shaping our industry?